<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 獲取免費報告) 的股價在週一的交易中跌破了其 200 日移動平均線。該股票的 200 日移動平均線為 2.30 美元，最低交易價為 2.11 美元。Oramed Pharmaceuticals 的股票最後交易價為 2.12 美元，成交量為 21,385 股。</p>
<p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>另外，華爾街 Zen 在 5 月 17 日的研究報告中將 Oramed Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。</p>
<p><strong>獲取我們最新的 ORMP 股票報告</strong></p>
<h2>Oramed Pharmaceuticals 股票表現</h2>
<p>該股票的 50 日移動平均線為 2.21 美元，200 日移動平均線為 2.30 美元。該股票的市值為 8660 萬美元，市盈率為 19.27，貝塔值為 1.65。</p>
<p>Oramed Pharmaceuticals (NASDAQ:ORMP - 獲取免費報告) 最近在 5 月 15 日發佈了其財報。這家生物技術公司報告本季度每股收益（EPS）為-0.19 美元，低於分析師一致預期的-0.03 美元，差距為-0.16 美元。該公司本季度的收入為 200 萬美元。股票研究分析師預測 Oramed Pharmaceuticals Inc.將在本年度發佈-0.03 的每股收益。</p>
<h2>對 Oramed Pharmaceuticals 的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近對其在 ORMP 的持倉進行了調整。BML Capital Management LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 14.3%。BML Capital Management LLC 目前擁有 3020748 股該生物技術公司的股票，價值 6464000 美元，此前在此期間又購買了 376841 股。Boothbay Fund Management LLC 在第四季度將其在 Oramed Pharmaceuticals 的持倉增加了 2.0%。Boothbay Fund Management LLC 目前擁有 845188 股該生物技術公司的股票，價值 2045000 美元，此前在此期間又購買了 16857 股。Peapod Lane Capital LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 11.0%。Peapod Lane Capital LLC 目前擁有 252224 股該生物技術公司的股票，價值 540000 美元，此前在此期間又購買了 24985 股。Dimensional Fund Advisors LP 在第四季度將其在 Oramed Pharmaceuticals 的持倉增加了 143.8%。Dimensional Fund Advisors LP 目前擁有 118995 股該生物技術公司的股票，價值 288000 美元，此前在此期間又購買了 70190 股。最後，Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 35.3%。Jane Street Group LLC 目前擁有 67173 股該生物技術公司的股票，價值 144000 美元，此前在此期間又購買了 17510 股。12.73% 的股票由機構投資者持有。</p>
<h2>Oramed Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Oramed Pharmaceuticals Inc.從事用於治療糖尿病的藥物解決方案的研究與開發，以及用於口服攝入膠囊以遞送多肽的研究。該公司的產品組合包括 ORMD-0801，一種口服胰島素膠囊，目前正在進行針對糖尿病患者的第三階段臨牀試驗，以及針對非酒精性脂肪肝炎的第二階段臨牀試驗；以及 ORA-D-013-1 和 ORA-D-013-2，這兩者已完成針對 2 型糖尿病的第二階段臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Oramed Pharmaceuticals</li>
<li>百分比漲幅對投資者的啓示及其未能傳達的全部故事</li>
<li>Workday 股價暴跌：AI 投資者的自動買入機會</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>MercadoLibre 股價飆升——你應該等待更好的入場時機嗎？</li>
<li>什麼是日經 225 指數？</li>
<li>對市場有疑慮？三隻股票幫助你度過恐懼、不確定性和懷疑</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Oramed Pharmaceuticals 嗎？</h2>
<p>在考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，建議在更廣泛的市場注意到之前購買……而 Oramed Pharmaceuticals 並不在名單上。</p>
<p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Oramed制藥

<p>Oramed 製藥（NASDAQ:ORMP）股票跌破其 200 日移動平均線 2.30 美元，當前交易價格為 2.12 美元，成交量為 21,385 股。該公司報告每股虧損 0.19 美元，低於預期 0.16 美元，季度收入為 200 萬美元。分析師已將該股票評級從 “持有” 下調至 “賣出”。機構投資者持有該股票的 12.73%，多家對沖基金近期增加了其持倉。Oramed 專注於通過口服胰島素膠囊和其他多肽遞送方法治療糖尿病</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.30 and traded as low as $2.11. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 21,385 shares trading hands.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 獲取免費報告) 的股價在週一的交易中跌破了其 200 日移動平均線。該股票的 200 日移動平均線為 2.30 美元，最低交易價為 2.11 美元。Oramed Pharmaceuticals 的股票最後交易價為 2.12 美元，成交量為 21,385 股。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Separately, Wall Street Zen cut Oramed Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, May 17th.</p>
<div class="lb-trans"><p>另外，華爾街 Zen 在 5 月 17 日的研究報告中將 Oramed Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。</p>
</div><p><strong>Get Our Latest Stock Report on ORMP</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 ORMP 股票報告</strong></p>
</div><h2>Oramed Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 股票表現</h2>
</div><p>The stock's fifty day moving average is $2.21 and its 200 day moving average is $2.30. The stock has a market cap of $86.60 million, a P/E ratio of 19.27 and a beta of 1.65.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 2.21 美元，200 日移動平均線為 2.30 美元。該股票的市值為 8660 萬美元，市盈率為 19.27，貝塔值為 1.65。</p>
</div><p>Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. Equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals (NASDAQ:ORMP - 獲取免費報告) 最近在 5 月 15 日發佈了其財報。這家生物技術公司報告本季度每股收益（EPS）為-0.19 美元，低於分析師一致預期的-0.03 美元，差距為-0.16 美元。該公司本季度的收入為 200 萬美元。股票研究分析師預測 Oramed Pharmaceuticals Inc.將在本年度發佈-0.03 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Oramed Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Oramed Pharmaceuticals 的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in ORMP. BML Capital Management LLC raised its position in shares of Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock valued at $6,464,000 after purchasing an additional 376,841 shares during the period. Boothbay Fund Management LLC raised its position in shares of Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares during the period. Peapod Lane Capital LLC raised its position in shares of Oramed Pharmaceuticals by 11.0% in the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對其在 ORMP 的持倉進行了調整。BML Capital Management LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 14.3%。BML Capital Management LLC 目前擁有 3020748 股該生物技術公司的股票，價值 6464000 美元，此前在此期間又購買了 376841 股。Boothbay Fund Management LLC 在第四季度將其在 Oramed Pharmaceuticals 的持倉增加了 2.0%。Boothbay Fund Management LLC 目前擁有 845188 股該生物技術公司的股票，價值 2045000 美元，此前在此期間又購買了 16857 股。Peapod Lane Capital LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 11.0%。Peapod Lane Capital LLC 目前擁有 252224 股該生物技術公司的股票，價值 540000 美元，此前在此期間又購買了 24985 股。Dimensional Fund Advisors LP 在第四季度將其在 Oramed Pharmaceuticals 的持倉增加了 143.8%。Dimensional Fund Advisors LP 目前擁有 118995 股該生物技術公司的股票，價值 288000 美元，此前在此期間又購買了 70190 股。最後，Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持倉增加了 35.3%。Jane Street Group LLC 目前擁有 67173 股該生物技術公司的股票，價值 144000 美元，此前在此期間又購買了 17510 股。12.73% 的股票由機構投資者持有。</p>
</div><h2>Oramed Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc.從事用於治療糖尿病的藥物解決方案的研究與開發，以及用於口服攝入膠囊以遞送多肽的研究。該公司的產品組合包括 ORMD-0801，一種口服胰島素膠囊，目前正在進行針對糖尿病患者的第三階段臨牀試驗，以及針對非酒精性脂肪肝炎的第二階段臨牀試驗；以及 ORA-D-013-1 和 ORA-D-013-2，這兩者已完成針對 2 型糖尿病的第二階段臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>What is the Nikkei 225 index?</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Oramed Pharmaceuticals</li>
<li>百分比漲幅對投資者的啓示及其未能傳達的全部故事</li>
<li>Workday 股價暴跌：AI 投資者的自動買入機會</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>MercadoLibre 股價飆升——你應該等待更好的入場時機嗎？</li>
<li>什麼是日經 225 指數？</li>
<li>對市場有疑慮？三隻股票幫助你度過恐懼、不確定性和懷疑</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Oramed Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，建議在更廣泛的市場注意到之前購買……而 Oramed Pharmaceuticals 並不在名單上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Oramed 製藥（NASDAQ:ORMP）的股票跌破了 200 日移動平均線 - 你應該賣出嗎？